These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

523 related articles for article (PubMed ID: 25868955)

  • 1. Effective eculizumab therapy followed by BMT in a boy with paroxysmal nocturnal hemoglobinuria.
    Oshiro H; Goi K; Akahane K; Inukai T; Sugita K
    Pediatr Int; 2015 Apr; 57(2):e27-9. PubMed ID: 25868955
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of immunosuppressive therapy in a patient with aplastic anemia-paroxysmal nocturnal hemoglobinuria (AA-PNH) syndrome during ongoing eculizumab treatment.
    Asano J; Ueda R; Tanaka Y; Shinzato I; Takafuta T
    Intern Med; 2014; 53(2):125-8. PubMed ID: 24429452
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Hematopoietic stem cell transplantation for aplastic anemia and paroxysmal nocturnal hemoglobinuria: current evidence and recommendations.
    Marotta S; Pagliuca S; Risitano AM
    Expert Rev Hematol; 2014 Dec; 7(6):775-89. PubMed ID: 25331515
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Successful use of eculizumab in a pediatric patient treated for paroxysmal nocturnal hemoglobinuria.
    Bauters T; Bordon V; Robays H; Benoit Y; Dhooge C
    J Pediatr Hematol Oncol; 2012 Nov; 34(8):e346-8. PubMed ID: 22767128
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prognostic factors and follow-up parameters in patients with paroxysmal nocturnal hemoglobinuria (PNH): experience of the Austrian PNH network.
    Füreder W; Sperr WR; Heibl S; Zebisch A; Pfeilstöcker M; Stefanzl G; Jäger E; Greiner G; Schwarzinger I; Kundi M; Keil F; Hoermann G; Bettelheim P; Valent P
    Ann Hematol; 2020 Oct; 99(10):2303-2313. PubMed ID: 32856141
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Paroxysmal nocturnal hemoglobinuria].
    Peffault de Latour R; Amoura Z; Socié G
    Rev Med Interne; 2010 Mar; 31(3):200-7. PubMed ID: 19303177
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Beneficial effects of eculizumab regardless of prior transfusions or bone marrow disease: Results of the International Paroxysmal Nocturnal Hemoglobinuria Registry.
    Röth A; Araten DJ; Larratt L; Kulasekararaj AG; Maciejewski JP; Wilson A; Gustovic P; Kanakura Y
    Eur J Haematol; 2020 Nov; 105(5):561-570. PubMed ID: 32640047
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Eculizumab Bridging before Bone Marrow Transplant for Marrow Failure Disorders Is Safe and Does Not Limit Engraftment.
    DeZern AE; Jones RJ; Brodsky RA
    Biol Blood Marrow Transplant; 2018 Dec; 24(12):e26-e30. PubMed ID: 30055352
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Paroxysmal nocturnal hemoglobinuria and the age of therapeutic complement inhibition.
    Varela JC; Brodsky RA
    Expert Rev Clin Immunol; 2013 Nov; 9(11):1113-24. PubMed ID: 24168416
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Strategy for bone marrow transplantation in eculizumab-treated paroxysmal nocturnal hemoglobinuria.
    Taniguchi K; Okada M; Yoshihara S; Sawada A; Tokugawa T; Ishii S; Kaida K; Ikegame K; Minagawa K; Matsui T; Ogawa H
    Int J Hematol; 2011 Oct; 94(4):403-407. PubMed ID: 21927799
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Post-Allogeneic Hematopoietic Stem Cell Transplantation Eculizumab as Prophylaxis Against Hemolysis and Thrombosis for Patients with Hematologic Disorders Associated with Paroxysmal Nocturnal Hemoglobinuria Clones.
    Mei M; Gupta R; O'Donnell M; Al Malki MM; Aldoss I; Ali H; Farol L; Snyder D; Forman SJ; Nakamura R; Khaled S
    Biol Blood Marrow Transplant; 2019 May; 25(5):e183-e185. PubMed ID: 30708188
    [TBL] [Abstract][Full Text] [Related]  

  • 12. How I treat paroxysmal nocturnal hemoglobinuria.
    Brodsky RA
    Blood; 2021 Mar; 137(10):1304-1309. PubMed ID: 33512400
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A cascade of thromboembolic processes in a patient with paroxysmal nocturnal haemoglobinuria terminated by treatment with eculizumab.
    Schutgens RE; Pruissen-Peeters KA; Muus P
    Thromb Haemost; 2011 Aug; 106(2):383-5. PubMed ID: 21655680
    [No Abstract]   [Full Text] [Related]  

  • 14. Hematopoietic Cell Transplantation for Paroxysmal Nocturnal Hemoglobinuria in the Age of Eculizumab.
    Cooper JP; Farah RJ; Stevenson PA; Gooley TA; Storb R; Scott BL
    Biol Blood Marrow Transplant; 2019 Jul; 25(7):1331-1339. PubMed ID: 30711779
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Successful cholecystectomy in a patient with aplastic anemia-paroxysmal nocturnal hemoglobinuria during eculizumab treatment.
    Ando K; Gotoh A; Yoshizawa S; Gotoh M; Iwabuchi T; Ito Y; Ohyashiki K
    Ann Hematol; 2012 Dec; 91(12):1987-8. PubMed ID: 22739575
    [No Abstract]   [Full Text] [Related]  

  • 16. Effectiveness of eculizumab in patients with paroxysmal nocturnal hemoglobinuria (PNH) with or without aplastic anemia in the International PNH Registry.
    Lee JW; Peffault de Latour R; Brodsky RA; Jang JH; Hill A; Röth A; Schrezenmeier H; Wilson A; Marantz JL; Maciejewski JP
    Am J Hematol; 2019 Jan; 94(1):E37-E41. PubMed ID: 30370949
    [No Abstract]   [Full Text] [Related]  

  • 17. Successful unrelated donor bone marrow transplantation for paroxysmal nocturnal hemoglobinuria.
    Woodard P; Wang W; Pitts N; Benaim E; Horwitz E; Cunningham J; Bowman L
    Bone Marrow Transplant; 2001 Mar; 27(6):589-92. PubMed ID: 11319587
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Anticomplement C5 therapy with eculizumab for the treatment of paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome.
    Wong EK; Kavanagh D
    Transl Res; 2015 Feb; 165(2):306-20. PubMed ID: 25468487
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Horse anti-thymocyte globulin and eculizumab as concomitant therapeutic approach in an aplastic paroxysmal nocturnal hemoglobinuria patient: go or no-go?
    Alashkar F; Dührsen U; Röth A
    Eur J Haematol; 2016 Oct; 97(4):403-5. PubMed ID: 26990688
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Achievements and limitations of complement inhibition by eculizumab in paroxysmal nocturnal hemoglobinuria: the role of complement component 3.
    Risitano AM; Perna F; Selleri C
    Mini Rev Med Chem; 2011 Jun; 11(6):528-35. PubMed ID: 21561403
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 27.